CVCT 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012

évènement
Mise en ligne : 01 décembre 2012
DOI : 10.60527/t7th-6045
URL pérenne : https://doi.org/10.60527/t7th-6045
  • niveau 1 niveau 2 niveau 3
  • document 1 document 2 document 3
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Holger WOEHRLE)

Vidéos

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Holger WOEHRLE)
Conférence
00:06:29

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspectiv…

Woehrle
Holger

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/or non-blinded trials (Stuart POCOCK)
Conférence
00:23:13

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/…

Pocock
Stuart J.

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joerg KOGLIN)
Conférence
00:07:08

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joer…

Koeck
Jean-Louis

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)
Conférence
00:09:32

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…

Prasad
Krishna

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Faiez ZANNAD)
Conférence
00:52:36

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…

Zannad
Faiez

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Efthymios DELIARGYRIS)
Conférence
00:13:06

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…

Deliargyris
Efthymios

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Freek VERHEUGT)
Conférence
00:26:04

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, differe…

Verheugt
Freek

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Michael GIBSON)
Conférence
01:09:44

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optima…

Gibson
Michael

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG)
Conférence
00:15:02

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods…

Koenig
Wolfgang

MODIGLIANI Workshop 2 - Friday November 30, 2012 : ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS Facilitating the discovery of effective therapies Chairpersons: Jagat NARULA, New York, USA - Ahmed

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Options of and alternatives to the “control group” in device trials (William T. ABRAHAM)
Conférence
00:16:44

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Options of and alte…

Abraham
William T.

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Nancy GELLER)
Conférence
00:12:25

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optima…

Geller
Nancy L.

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST  (Michael FELKER)
Conférence
00:12:12

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story …

Felker
G. Michael

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST  (William T. ABRAHAM)
Conférence
00:12:13

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story …

Abraham
William T.

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration for acute cardiorenal syndrome in heart failure (Gian Paolo ROSSI)
Conférence
00:51:34

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration fo…

Rossi
Gian Paolo

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE and gaps in evidence with diuretic therapy (Alice MASCETTE)
Conférence
00:31:41

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE…

Mascette
Alice

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for securing approval and reimbursement (Andrew FARB - Ileana PIÑA)
Conférence
00:22:56

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for …

Pina
Ileana
Farb
Andrew

MODIGLIANI Debate Session 4 - Saturday December 1st, 2012: HEART FAILURE REMOTE MONITORING TRIALS Chairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USA Webcast: Daniela DOBRE, Nancy,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimization (William T. ABRAHAM)
Conférence
00:28:04

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimiza…

Abraham
William T.

MODIGLIANI Debate Session 4 - Saturday December 1st, 2012: HEART FAILURE REMOTE MONITORING TRIALS Chairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USA Webcast: Daniela DOBRE, Nancy,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoint  (Yuki ANDO)
Conférence
00:13:53

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoin…

Ando
Yuki

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : The value of repeat events in post discharge hospitalized HF trials (Stuart POCOCK)
Conférence
00:34:34

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : The value of repeat…

Pocock
Stuart J.

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :Regulatory viewpoint (Pieter DE GRAEF)
Conférence
00:36:29

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :Regulatory viewpoint (Pie…

Graef
Pieter de

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Roxana MEHRAN)
Conférence
00:12:25

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and r…

Mehran
Roxana

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Rob KIEVAL)
Conférence
00:08:52

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspectiv…

Kieval
Rob

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effectiveness studies (Rita REDBERG)
Conférence
00:33:42

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effecti…

Redberg
Rita F.

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effectiveness studies (Kenneth STEIN)
Conférence
00:21:52

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effecti…

Stein
Kenneth

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Ileana PIÑA)
Conférence
00:10:07

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and r…

Pina
Ileana

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issues: Pathway to a more global device approval process (Ileana PIÑA)
Conférence
01:17:56

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issue…

Pina
Ileana

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : PET-CT imaging in clinical trials (James RUDD)
Conférence
00:33:59

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : PET-CT imaging in clinic…

Rudd
James

MODIGLIANI Workshop 2 - Friday November 30, 2012 : ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS Facilitating the discovery of effective therapies Chairpersons: Jagat NARULA, New York, USA - Ahmed

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Yasser KHDER)
Conférence
00:06:43

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Yass…

Khder
Yasser

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Maarten SIMOONS)
Conférence
00:17:48

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, differe…

Simoons
Maarten L.

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Lloyd HASKEL)
Conférence
00:12:36

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…

Haskel
Lloyd

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Kaori SHINAGAWA)
Conférence
00:08:24

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Ka…

Shinagawa
Kaori

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Christophe GAUDIN)
Conférence
00:08:07

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Chri…

Gaudin
Christophe

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Angeles ALONSO)
Conférence
00:07:13

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (An…

Alonso
Angeles

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.
Conférence
00:29:24

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and…

Maggioni
Aldo

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries • NICE Speaker: Suzanna HARDMAN, London, GBR • German CHF registry:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.
Conférence
00:13:56

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and…

Tschoepe
Carsten

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries. • NICE Speaker: Suzanna HARDMAN, London, GBR • German CHF registry:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion
Conférence
00:07:27

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion

Bakris
George L.
Kjeldsen
Sverre Erik

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NOR Abstract : conclusion L’auteur n’a pas transmis de conflit

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Conférence
00:04:13

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in a…

Stein
Kenneth

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Conférence
00:19:42

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in a…

Farb
Andrew

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Conférence
00:08:37

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in a…

Bakris
George L.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials
Conférence
00:11:49

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for hear…

Zannad
Faiez

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials Speaker: Faiez ZANNAD, Nancy, FRA Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments
Conférence
00:07:21

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and futur…

Yared
Nadim

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments Speaker: Hermann HALLER, Hannover, GER Discussant: Nadim YARED, CVRx, USA

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?
Conférence
00:14:04

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can re…

Azizi
Michel

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure? Speaker: Felix MAHFOUD, Homburg, GER Discussant

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?
Conférence
00:14:44

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can re…

Mahfoud
Felix

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure? Speaker: Felix MAHFOUD, Homburg, GER Discussant

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.
Should there be a position statement establishing rules for biomarker studies?
Conférence
00:04:01

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There …

Fiuzat
Mona

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.
Should there be a position statement establishing rules for biomarker studies?
Conférence
00:03:23

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There …

Redberg
Rita F.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
Conférence
00:17:29

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there o…

Felker
G. Michael

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures Speaker:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
Conférence
00:10:00

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for…

Blankenberg
Stefan
Geller
Nancy L.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates). Speaker: Stefan BLANKENBERG, Hamburg, GER

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Conférence
00:07:58

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluati…

Geller
Nancy L.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Conférence
00:14:50

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluati…

Blankenberg
Stefan

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Conférence
00:15:36

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic mark…

Snider
James

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Conférence
00:16:36

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic mark…

Januzzi
Jim

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Conférence
00:13:18

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints

Redberg
Rita F.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints Speaker: Joseph LOSCALZO, Boston, USA, Circulation Discussant: Rita REDBERG, San Francisco, USA, Arch

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Conférence
00:04:37

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints

Jarcho
John

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints Speaker: John JARCHO, Boston, USA, NEJM Discussant: Rita REDBERG, San Francisco, USA, Arch Intern Med

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers
Conférence
00:36:51

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers

Blankenberg
Stefan

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers Speaker: Stefan BLANKENBERG, Hamburg, GER Abstract : The role of biomarkers L’auteur n’a pas transmis de

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine
How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
Conférence
00:41:45

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biol…

Torp-Pedersen
Christian

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine
How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
Conférence
00:13:32

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Ke…

Torp-Pedersen
Christian

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine
How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
Conférence
00:17:43

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Ke…

Zannad
Faiez

How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations. ISCP: Speaker: Felipe MARTINEZ, Cordoba, ARG CVCT: Speaker: Faiez ZANNAD, Nancy, FRA ESC

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance?
Conférence
00:32:48

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class…

Pitt
Bertram

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance? Speaker: Bertram

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Compound vs. class effect. Drug class recommendations in guidelinesCanadian, Australian CHF guideline and 2010 NICE guideline.
Conférence
00:12:31

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Compound vs. class effect. Drug class…

Ezekowitz
Justin

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Compound vs. class effect. Drug class recommendations in guidelinesCanadian, Australian CHF guideline and 2010 NICE guideline.

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failure epidemiology.
Conférence
00:37:34

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failur…

Ezekowitz
Justin

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failure epidemiology. Speaker: Justin EZEKOWITZ, Edmonton, CAN Abstract : Expected implications on

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…
Conférence
00:11:34

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ES…

Zannad
Faiez

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…

Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.
Conférence
00:14:10

Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.

Graef
Pieter de

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues. Industry viewpoint: Paul AUDHYA, Reata, USA Regulatory viewpoint: Pieter DE GRAEF, EMEA, NED Abstract

Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)
Conférence
00:22:31

Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor ant…

Rossignol
Patrick

Title : Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST) Speaker: Patrick ROSSIGNOL, Nancy, FRA Abstract : RAAS

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).
Conférence
00:09:24

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…

Massy
Ziad

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates). Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
Conférence
00:10:17

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…

Mix
Chris

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
Conférence
00:10:30

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…

Massy
Ziad

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.
Conférence
00:20:05

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…

Wheeler
David

Title: Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients. Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)
Conférence
00:26:39

Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SH…

Baigent
Colin

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA) Speaker: Colin BAIGENT, Oxford, GBR Abstract : Lipid lowering agents. Now,

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.
Conférence
00:46:30

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradi…

Cowie
Martin

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine. Speaker: Martin COWIE, London, GBR Abstract :  Clinical evidence suggests that an

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.
Conférence
00:57:34

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure ma…

Borer
Jeffrey S.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management. Speaker: Jeffrey BORER, New York, USA Abstract : SHIFT (Systolic Heart failure

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparator
Conférence
00:19:18

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : o…

Marre
Michel
Roussel
Ronan

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparator Speaker: Michel

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance
Conférence
00:12:25

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both…

Dunder
Kristina

Title :Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance Speaker: Marc PFEFFER, Boston, USA Discussant: Stuart

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance
Conférence
00:15:46

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both…

Pocock
Stuart J.

Title: Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance Speaker: Marc PFEFFER, Boston, USA Discussant: Stuart

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipids, BP, Weight, Kidney
Conférence
00:15:00

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipid…

Bonds
Denise

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipids, BP, Weight, Kidney Speaker: Denise BONDS, NHLBI, USA Abstract : What else than glucose

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : Insulin in type 2 diabetes: bad guy or good guy?
Conférence
00:17:12

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : I…

Marre
Michel

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : Insulin in type 2 diabetes: bad guy or good guy? Speaker: Michel MARRE, Paris, FRA Abstract :

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? (debates)
Conférence
00:44:47

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-st…

Hernandez
Adrian Felipe

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? (debates)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
Conférence
00:09:45

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-st…

Hernandez
Adrian Felipe

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? Speaker: Wolfgang KOENIG, Ulm, GER Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
Conférence
00:13:23

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-st…

Koenig
Wolfgang

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? Speaker: Wolfgang KOENIG, Ulm, GER Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries (debates).
Conférence
00:19:16

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epi…

Sobhy
Mohamed

Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries (debates). Prem PAIS, Bangalore, IND Speaker: Mohamed SOBHY, Alexandria, EGY Abstract :

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
Conférence
00:11:49

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epi…

Sobhy
Mohamed

Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries Speaker: Mohamed SOBHY, Alexandria, EGY Abstract : Diabetes is one of the major public health

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
Conférence
00:14:53

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epi…

Pais
Prem

Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries Speaker: Prem PAIS, Bangalore, IND Abstract : India has a high prevalence of type 2 diabetes

Intervenants et intervenantes